Skip to main content
Top
Published in: Clinical Rheumatology 5/2019

Open Access 01-05-2019 | Lymphoma | Original Article

Usefulness of rheumatoid factor as an immunological and prognostic marker in PSS patients

Authors: Maria Maślińska, Małgorzata Mańczak, Brygida Kwiatkowska

Published in: Clinical Rheumatology | Issue 5/2019

Login to get access

Abstract

Introduction

The rheumatoid factor (RF) is present in numerous autoimmune disorders, although its role in many of them remains a subject of research. The study assesses the role of RF as an immunological and prognostic factor in the primary Sjögren’s syndrome (pSS).

Methods

Seventy-five pSS patients (mean age 50.03 ± 15.1), 65 (87%) females, and 10 (13%) males. WBC, CRP, RF, ESR, gammaglobulins, C4, C3 component of complement, cryoglobulins, ANA, anti-SS-A, and anti-SS-B antibodies were determined. The disease activity assessed with ESSDAI. Minor salivary gland biopsy (focus score and immunochemistry) was conducted. Results were analyzed with U Mann-Whitney (continuous variables) tests, correlations between quantitative variables assessed with the Spearman correlation coefficient with statistical significance set at p < 0.05. The approval of the Bioethics Committee was obtained.

Results

Two subgroups I-RF(+) (61%) and II-RF(−) (39%) were established, with lower WBC (p = 0.012) and higher ESR (p = 0.016), gammaglobulin concentration (p = 0.007) in group I. Conjunctivitis sicca was more severe in group I. There was positive correlation between RF and lnANA (rho = 0.496), anti-SS-A, anti-SS-B antibodies (rho = 0.448; rho = 0.397 respectively). There was higher disease activity ESSDAI in group I than in group II (Me, 3.0 vs 2.0; p < 0.003). RF correlated negatively with WBC (rho = − 0.374). RF did not correlate with serum concentrations of BAFF, APRIL, CRP, and C3, C4 and with CD19+, CD3+, CD4+, CD 21+, and CD35+.

Conclusions

RF should be considered as a prognostic, but not diagnostic, factor in patients with pSS, as it is associated with more severe disease course (sicca eye symptoms, ESSDAI) and parameters (production of gammaglobulins, ANA, anti SS-A, anti-SS-B autoantibodies) indicating increased B cell activity.
Literature
2.
go back to reference Haberman AM, William J, Euler C, Shlomchik MJ (2003) Rheumatoid factors in health and disease: structure, function, induction and regulation. Curr Dir Autoimmun 6:169–195CrossRefPubMed Haberman AM, William J, Euler C, Shlomchik MJ (2003) Rheumatoid factors in health and disease: structure, function, induction and regulation. Curr Dir Autoimmun 6:169–195CrossRefPubMed
4.
5.
go back to reference Cornec D, Saraux A, Pers JO, Jousse-Joulin S, Marhadour T, Roguedas-Contios AM, Genestet S, Renaudineau Y, Devauchelle-Pensec V (2014) Diagnostic accuracy of blood B-cell subset profiling and autoimmunity markers in primary Sjogren’s syndrome. Arthritis Res Ther 16:R15CrossRefPubMedPubMedCentral Cornec D, Saraux A, Pers JO, Jousse-Joulin S, Marhadour T, Roguedas-Contios AM, Genestet S, Renaudineau Y, Devauchelle-Pensec V (2014) Diagnostic accuracy of blood B-cell subset profiling and autoimmunity markers in primary Sjogren’s syndrome. Arthritis Res Ther 16:R15CrossRefPubMedPubMedCentral
7.
go back to reference Nielsen SF, Bojeson SE, Schnohr P, Nordestaarg BG (2012) Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study. BMJ 345:e5244CrossRefPubMedPubMedCentral Nielsen SF, Bojeson SE, Schnohr P, Nordestaarg BG (2012) Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study. BMJ 345:e5244CrossRefPubMedPubMedCentral
8.
go back to reference Simard JF (2012) Rheumatoid factor positivity in the general population. Is unlikely to be discovered incidentally. BMJ 345:e5841CrossRefPubMed Simard JF (2012) Rheumatoid factor positivity in the general population. Is unlikely to be discovered incidentally. BMJ 345:e5841CrossRefPubMed
9.
go back to reference Newkirk MM, Lepage K, Niwa T, Rubin L (1998) Advanced glycation endproducts (AGE) on IgG, a target for circulating antibodies in North American Indians with Rheumatoid Arthritis (RA). Cell Molec Biol 44:1129–1138 Newkirk MM, Lepage K, Niwa T, Rubin L (1998) Advanced glycation endproducts (AGE) on IgG, a target for circulating antibodies in North American Indians with Rheumatoid Arthritis (RA). Cell Molec Biol 44:1129–1138
10.
go back to reference Mavragani CP, Crow MK (2010) Activation of the type I interferon pathway in primary Sjögren’s syndrome. J Autoimmun 35:225–231CrossRefPubMed Mavragani CP, Crow MK (2010) Activation of the type I interferon pathway in primary Sjögren’s syndrome. J Autoimmun 35:225–231CrossRefPubMed
12.
go back to reference Diaz-Lopez C, Geli C, Corominasetal H (2004) Are there clinical or serological differences between male and female patients with primary Sjögren’s syndrome? J Rheumatol 31(7):1352–1355PubMed Diaz-Lopez C, Geli C, Corominasetal H (2004) Are there clinical or serological differences between male and female patients with primary Sjögren’s syndrome? J Rheumatol 31(7):1352–1355PubMed
13.
go back to reference Shiboski SC, Shiboski CH, Criswell L et al (2012) American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 64:475–487CrossRef Shiboski SC, Shiboski CH, Criswell L et al (2012) American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 64:475–487CrossRef
14.
go back to reference Ramos-Casals M, Font J, Garcia-Carrasco M, , et al. Primary Sjogren syndrome: hematologic patterns of disease expression. (2002) Medicine (Baltimore) 81: 281–292CrossRef Ramos-Casals M, Font J, Garcia-Carrasco M, , et al. Primary Sjogren syndrome: hematologic patterns of disease expression. (2002) Medicine (Baltimore) 81: 281–292CrossRef
15.
go back to reference Witte T, Hartung K, Sachse C et al (2000) Rheumatoid factors in systemic lupus erythematosus: association with clinical and laboratory parameters. SLE study group. Rheumatol Int 19:107–111CrossRefPubMed Witte T, Hartung K, Sachse C et al (2000) Rheumatoid factors in systemic lupus erythematosus: association with clinical and laboratory parameters. SLE study group. Rheumatol Int 19:107–111CrossRefPubMed
16.
go back to reference Nocturne G, Virone A, Ng W-F, le Guern V, Hachulla E, Cornec D, Daien C, Vittecoq O, Bienvenu B, Marcelli C, Wendling D, Amoura Z, Dhote R, Lavigne C, Fior R, Gottenberg JE, Seror R, Mariette X (2016) Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjögren’s syndrome. Arthritis Rheumatol 68:977–985CrossRefPubMed Nocturne G, Virone A, Ng W-F, le Guern V, Hachulla E, Cornec D, Daien C, Vittecoq O, Bienvenu B, Marcelli C, Wendling D, Amoura Z, Dhote R, Lavigne C, Fior R, Gottenberg JE, Seror R, Mariette X (2016) Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjögren’s syndrome. Arthritis Rheumatol 68:977–985CrossRefPubMed
17.
go back to reference Watanabe S, Gono T, Nishina K, Sugitani N, Watanabe E, Yabe H, Terai C (2017) Rheumatoid factor is correlated with disease activity and inflammatory markers in antineutrophil cytoplasmic antibody- associated vasculitis. BMC Immunol 18:53CrossRefPubMedPubMedCentral Watanabe S, Gono T, Nishina K, Sugitani N, Watanabe E, Yabe H, Terai C (2017) Rheumatoid factor is correlated with disease activity and inflammatory markers in antineutrophil cytoplasmic antibody- associated vasculitis. BMC Immunol 18:53CrossRefPubMedPubMedCentral
18.
go back to reference Flores-Chávez A, Kostov B, Solans R et al (2018) Severe, life-threatening phenotype of primary Sjögren’s syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry). Clin Exp Rheumatol 36 Suppl 112(3):121–129PubMed Flores-Chávez A, Kostov B, Solans R et al (2018) Severe, life-threatening phenotype of primary Sjögren’s syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry). Clin Exp Rheumatol 36 Suppl 112(3):121–129PubMed
19.
go back to reference Birnbaum J, Lalji A, Saed A, Baer AN (2018) Biopsy-proven small-fiber neuropathy in primary Sjögren’s syndrome: neuropathic pain characteristics, autoantibody findings, and histopathological features. Arthritis Care Res (Hoboken). https://doi.org/10.1002/acr.23762 Birnbaum J, Lalji A, Saed A, Baer AN (2018) Biopsy-proven small-fiber neuropathy in primary Sjögren’s syndrome: neuropathic pain characteristics, autoantibody findings, and histopathological features. Arthritis Care Res (Hoboken). https://​doi.​org/​10.​1002/​acr.​23762
20.
go back to reference Gottenberg JE, Cinquetti G, Larroche C et al (2013) Efficacy of rituximab in systemic manifestations of primary Sjogren’s syndrome: results in 78 patients of the Autoimmune and Rituximab registry. Ann Rheum Dis 72:1026–1031CrossRefPubMed Gottenberg JE, Cinquetti G, Larroche C et al (2013) Efficacy of rituximab in systemic manifestations of primary Sjogren’s syndrome: results in 78 patients of the Autoimmune and Rituximab registry. Ann Rheum Dis 72:1026–1031CrossRefPubMed
21.
go back to reference Sada PR, Isenberg D, Ciurtin C (2015) Biologic treatment in Sjögren’s syndrome. Rheumatology (Oxford) 54:219–230CrossRef Sada PR, Isenberg D, Ciurtin C (2015) Biologic treatment in Sjögren’s syndrome. Rheumatology (Oxford) 54:219–230CrossRef
22.
go back to reference Maneiro RJ, Salgado E, Carmona L, Gomez-Reino JJ (2013) Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis. Semin Arthritis Rheum 43(1):9–17CrossRefPubMed Maneiro RJ, Salgado E, Carmona L, Gomez-Reino JJ (2013) Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis. Semin Arthritis Rheum 43(1):9–17CrossRefPubMed
23.
go back to reference Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Lei G, Williams S, Lal P, Read SJ (2013) Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 72(3):329–336CrossRefPubMed Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Lei G, Williams S, Lal P, Read SJ (2013) Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 72(3):329–336CrossRefPubMed
24.
Metadata
Title
Usefulness of rheumatoid factor as an immunological and prognostic marker in PSS patients
Authors
Maria Maślińska
Małgorzata Mańczak
Brygida Kwiatkowska
Publication date
01-05-2019
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 5/2019
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-019-04438-z

Other articles of this Issue 5/2019

Clinical Rheumatology 5/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine